DPYSL3B is a regulator of chemoresistance via DNA repair and metabolic reprogramming in prostate cancer

Roosa Kaarijärvi(University of Eastern Finland), Kirsi Ketola(University of Eastern Finland)

bioRxiv (Cold Spring Harbor Laboratory)

July 7, 2025

10.1101/2025.07.03.658029

Cited by 1

Related Papers

Fanconi anemia pathway regulation by FANCI in prostate cancer

|Frontiers in Oncology|2023|5

Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population

|InTech eBooks|2012|4

Supplementary Material-SM1 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity

|Unknown|2023|0